Clinical Trial Details
— Status: Not yet recruiting
Administrative data
| NCT number |
NCT06135441 |
| Other study ID # |
Bone manifestation |
| Secondary ID |
|
| Status |
Not yet recruiting |
| Phase |
|
| First received |
|
| Last updated |
|
| Start date |
December 1, 2023 |
| Est. completion date |
November 1, 2024 |
Study information
| Verified date |
November 2023 |
| Source |
Assiut University |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Observational
|
Clinical Trial Summary
Nutrients important to bones. Because bones undergo continuous remodeling, an adequate supply
of nutrient substrate is needed to support the formation phase of bone remodeling. In
addition to their passive roles as substrate for bone formation, dietary calcium and protein
play active roles in bone metabolism, as well as phosphorus and vitamin D. Other vitamins and
minerals are also needed for metabolic processes related to bone, directly or indirectly.
Description:
Nutrients important to bones. Because bones undergo continuous remodeling, an adequate supply
of nutrient substrate is needed to support the formation phase of bone remodeling. In
addition to their passive roles as substrate for bone formation, dietary calcium and protein
play active roles in bone metabolism, as well as phosphorus and vitamin D. Other vitamins and
minerals are also needed for metabolic processes related to bone, directly or indirectly.
The Food and Nutrition Board (FNB) of the National Academy of Sciences, has released in the
past few years the new Dietary Reference Intakes (DRI) based on the latest understanding
about nutrient requirements for optimizing health.
The fetal period, early life, childhood, and puberty are critical periods for the development
and/or programming of metabolic systems, including the skeleton. Osteoporosis is described by
the World Health Organization (WHO) as a progressive systemic skeletal disease characterized
by low bone mass and microarchitectural deterioration of bone tissue, with a consequent
increase in bone fragility and susceptibility to fracture. Because of the morbidity of
osteoporosis, the prevention of this disease and its associated fractures is considered
essential to the maintenance of health, quality of life, and independence in the elderly
population.
Peak bone mass attained during childhood and adolescence determines skeletal fragility in old
age.
Peak bone mass is the amount of bone acquired when accrual ceases or reaches a plateau at
some point after the completion of growth and development. Metabolic bone disease (MBD) is an
umbrella term that encompasses a broad spectrum of clinically different diseases that share
the common finding of an aberrant bone chemical milieu leading to a defective skeleton and
bone abnormalities. Metabolic bone diseases are usually characterized by a dramatic clinical
presentation and manifestation that are commonly reversible once the underlying defect has
been treated. Abnormalities of minerals include calcium, phosphorus, magnesium, or vitamin D
developing as a result of dysfunctions of the various factors that control mineral
homeostasis. The defective mineralization translates into rickets at the level of the
epiphyseal growth plates and osteomalacia on the endocortical and cancellous bone surfaces
Moreover, osteogenesis imperfecta (OI) pathogenesis has been expanded from a simple collagen
defect to abnormalities in bone cell metabolism and development with primary defects in
osteoblast differentiation. Metabolic bone disease is to be differentiated from skeletal
dysplasia which are a larger group of genetic bone disorders that overlaps with MBD. In
contrast to MBD, skeletal dysplasias are heritable diseases that have generalized
abnormalities in cartilage and bone. The primary defects are in specific signal system or
cell types that orchestrate processes of skeleton formation causing the bone disorder.
